Expect Pfizer bid to beat Novo for Metsera, says BMO's Evan David Seigerman

For more on all this, let's bring in Beimo head of healthc care research, Evan David Seager. Evan, great to have you with us. >> Thank you for having me.>> Um, this is really becoming a battle over Meter. Is Metera worth this much. And who is it worth more to, Novo or Fizer.>> Well, I think Metser is definitely worth this much. As you know, the obesity market is likely to be in our estimates upwards of $130 billion when you lump in diabetes. So, there is a big opportunity here.And right now, it's only Lily ...